Mauna Kea Technologies SAS
PAR:MKEA

Watchlist Manager
Mauna Kea Technologies SAS Logo
Mauna Kea Technologies SAS
PAR:MKEA
Watchlist
Price: 0.506 EUR -2.69%
Market Cap: €24.4m

Mauna Kea Technologies SAS
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mauna Kea Technologies SAS
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Mauna Kea Technologies SAS
PAR:MKEA
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Edap Tms SA
NASDAQ:EDAP
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biomerieux SA
PAR:BIM
Non-Reccuring Items
-€135.8m
CAGR 3-Years
N/A
CAGR 5-Years
-196%
CAGR 10-Years
-17%
Diagnostic Medical Systems SA
PAR:ALDMS
Non-Reccuring Items
€1.1m
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
N/A
S
SMAIO SA
PAR:ALSMA
Non-Reccuring Items
€19k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amplitude Surgical SA
PAR:AMPLI
Non-Reccuring Items
-€233k
CAGR 3-Years
61%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Mauna Kea Technologies SAS
Glance View

Market Cap
24.4m EUR
Industry
Health Care

Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2011-07-05. The firm focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The firm markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.

MKEA Intrinsic Value
Not Available

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett